Navigation Links
MediciNova Announces Positive Clinical Results From MN-166 Phase II,Multiple Sclerosis Trial

ng (T2)) cranial MRI lesions (the primary endpoint of the trial) and other MRI-related, exacerbation and disability-related endpoints (relapse rate and Expanded Disability Status Scale (EDSS) score) after 12 months of treatment. Eligible patients who elected to continue their participation in the trial after 12 months of treatment will continue to receive treatment and will be assessed at months 13, 14, 16, 18, 20, 22 and 24 of the trial; patients who received placebo during the first 12 months of the trial were randomized to receive either 30 or 60 mg of MN-166 per day (double-blind maintained) during the second 12 months of the trial.

About Multiple Sclerosis and MN-166

Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system (CNS), affecting approximately 250,000 - 350,000 people in the U.S. The most obvious effect of MS is the progressive loss of muscle control, but multiple brain and CNS functions are also affected. There is no cure for the disease. Relapsing-remitting MS (RRMS), which is the most common type of the disease, affects approximately 65% of MS patients according to a Cognos study published by Decision Resources, Inc. Most patients with RRMS eventually progress to the secondary progressive (SPMS) form of the disease.

MN-166 is a novel, orally administered compound being evaluated for the treatment of MS. MN-166 inhibits leukotriene activity, phosphodiesterases and nitric oxide synthase, all inflammatory mechanisms known to be involved in MS. MN-166 may also suppress the production of pro-inflammatory cytokines (IL-1beta, TNF-alpha) and may enhance the production of the anti-inflammatory cytokines (IL-4, IL-10). In two pilot clinical trials sponsored by academic investigators in Japan, MN-166 was found to have certain beneficial effects with respect to the treatment of MS.

MediciNova acquired an exclusive, worldwide (excluding Japan, China, Taiwan and South Korea), sublicensable licens
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:3/26/2015)... Over-the-counter healthcare costs can be a ... new survey of store brand over-the-counter products aimed ... to diabetes, can offer significant savings for those ... Private Label Manufacturers Association, assembled a market basket ... essential for treatment of pre-diabetes and diabetes. These ...
(Date:3/26/2015)... 2015  Desert Valley Medical Center, named a Top ... is the first U.S. hospital to deploy the wireless ... help clinicians prevent hospital acquired pressure ulcers. ... , is a community hospital serving some higher risk ... Patient Monitor in the hospital,s emergency department enables the ...
(Date:3/26/2015)... Californie, 26 mars 2015 Finesse Solutions ... conçu pour les innovateurs, visionnaires et cadres de ... conférence d,une durée de deux jours proposée exclusivement ... dans le centre ville de San ... 2015. Il s,agira d,un forum destiné aux leaders ...
Breaking Medicine Technology:Consumers can keep over-the-counter medicine affordable by using store brands 2Desert Valley Medical Center First to Use Leaf Healthcare Patient Wearable Technology in its ED as Part of Hospital-wide Deployment 2Desert Valley Medical Center First to Use Leaf Healthcare Patient Wearable Technology in its ED as Part of Hospital-wide Deployment 3Finesse Solutions annonce l'événement Cellworld 2015 2
... Its USD520.6 million Sale to Sanofi-... -- PARIS, Nov. 1, 2010 /PRNewswire-Asia/ -- ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // Results are keyed by longUrl, so we need ...
... NeoStem, Inc. (NYSE Amex: NBS ) ... operations in the U.S. and China, today announced that ... (China), Inc., the Company,s wholly-owned subsidiary, will present "Building ... Therapy Industry Summit 2010 hosted by Life Technologies Corporation ...
Cached Medicine Technology:E. J. McKay Advises BMP Sunstone on Its USD520.6 million Sale to Sanofi- aventis 2E. J. McKay Advises BMP Sunstone on Its USD520.6 million Sale to Sanofi- aventis 3E. J. McKay Advises BMP Sunstone on Its USD520.6 million Sale to Sanofi- aventis 4E. J. McKay Advises BMP Sunstone on Its USD520.6 million Sale to Sanofi- aventis 5E. J. McKay Advises BMP Sunstone on Its USD520.6 million Sale to Sanofi- aventis 6E. J. McKay Advises BMP Sunstone on Its USD520.6 million Sale to Sanofi- aventis 7E. J. McKay Advises BMP Sunstone on Its USD520.6 million Sale to Sanofi- aventis 8NeoStem to Present at Cell Therapy Industry Summit to be held on November 3-5, 2010 in Carlsbad, California 2NeoStem to Present at Cell Therapy Industry Summit to be held on November 3-5, 2010 in Carlsbad, California 3
(Date:3/26/2015)... “The SWEET Act is an important step ... available and help parents who are working to reduce sugar ... approach to support public health, and we will continue to ... health of all families,” said Dr. Jane Delgado President and ... introduction of the Sugar-Sweetened Beverage Tax (SWEET) Act by Congresswoman ...
(Date:3/26/2015)... Dr. Alex Rabinovich and his San Francisco ... for Bay Area patients considering dental implants or teeth ... been a top-rated center, serving primarily San Franciscans; however, ... strong demand by others throughout Northern California. , “We ... implant facility in San Francisco,”explained Dr. Alex Rabinovich, owner ...
(Date:3/26/2015)... Springs, FL (PRWEB) March 26, 2015 ... of the nation’s leading innovative specialty pharmacies, announces ... created position of Vice President of Pharmaceutical Relations. ... fostering beneficial connections with our pharmaceuticals partners and ... relationships in support of BioPlus’ expansion. , ...
(Date:3/26/2015)... UK (PRWEB) March 26, 2015 In the ... billion as of 2013 and is set to decrease through ... by 2020; the growth is expected up to 2017 at ... is expected to be owing to the surging penetration of ... HCT, Twynsta, Micardis Plus, Valturna, Benicar HCT, and Tekamlo), a ...
(Date:3/26/2015)... Sunrise, FL (PRWEB) March 26, 2015 ... unveiled its brand-new, state-of-the-art company website: http://www.metabolicnutrition.com ... of the revamped website creates a user-friendly experience ... supplement company. , The new, enhanced Metabolic ... Comprehensive information about the company’s diverse line of ...
Breaking Medicine News(10 mins):Health News:National Alliance for Hispanic Health Statement on Introduction of SWEET Act in 114th Congress 2Health News:Bay Area Dental Implant Specialist, Dr. Alex Rabinovich Announces Regional Educational Strategy 2Health News:Bay Area Dental Implant Specialist, Dr. Alex Rabinovich Announces Regional Educational Strategy 3Health News:BioPlus Specialty Pharmacy Expands Executive Team with New Position, Naming Sharon Ferrer as Vice President of Pharmaceutical Relations 2Health News:Top 8 Developed Anti-Hypertensive Therapeutics Markets Discussed in New GBI Research Report Published at MarketPublishers.com 2Health News:Top 8 Developed Anti-Hypertensive Therapeutics Markets Discussed in New GBI Research Report Published at MarketPublishers.com 3Health News:Metabolic Nutrition Launches Sleek New Website with New Features and Enhanced Consumer Information 2
... use of alternative or complementary therapies have increased over ... using // at least one form of alternative medicine. ... yoga, hypnosis, acupuncture, chiropractic care, and high-dose vitamins. ... own survey taken in 1997 to the National Health ...
... disorder, where white blood cells attack fatty tissue surrounding nerve ... is twice as common in women as in men . ... with multiple sclerosis. Since MS causes muscle weakness and fatigue, ... of life, researchers designed an exercise program to develop ...
... days of physical inactivity, the body's efficient use of insulin ... ,Researchers conducted a study in rats and found insulin sensitivity ... stopped running for two days after a period of running ... muscle in response to insulin was found to have decreased ...
... Duchenne muscular dystrophy (DMD) with the oral steroid prednisone is ... effects of the drug . Most patients with this form ... 20s from respiratory failure or heart problems. Despite the beneficial ... side effects, which can range from weight gain to behavioral ...
... people who carry a gene that produces a higher ... increased risk for stroke.// ,Researchers reviewed medical literature ... that previous study results were observational in nature. A ... factors by looking at data on the link between ...
... coronary heart disease who follow a heart-healthy diet and ... // medications that raise HDL (high-density lipoproteins or "good" ... studied 143 patients younger than 76 with low HDL ... study followed a heart-healthy diet and lost weight. However, ...
Cached Medicine News:
... Sun Med TruFlow™ Oxygen flowmeter with ... lifetime warranty covering calibration and manufacturing defects. ... to meet most needs. Also available with ... auxiliary power take-off and double unit configurations. ...
... TruFlow™ Oxygen flowmeter with a Lexan®inner calibrated ... calibration and manufacturing defects. A wide range ... needs. Also available with all popular inlet ... and double unit configurations. Our extra large ...
... Oxygen flowmeter with a Lexan®inner calibrated flow ... and manufacturing defects. A wide range of ... Also available with all popular inlet connections, ... double unit configurations. Our extra large knob ...
... Sun Med TruFlow™ Oxygen flowmeter with ... lifetime warranty covering calibration and manufacturing defects. ... to meet most needs. Also available with ... auxiliary power take-off and double unit configurations. ...
Medicine Products: